The rate of growth of health spending remains moderate. But one area where prices appear to be increasing faster than they have in the past few years is brand-name prescription drugs. By 2012, blockbusters had lost their patents, and many looked forward to a future where we could all get a month-long supply of generic drugs for $4. Well, it did not quite work out that way.
Read the entire article at Forbes.
Research and commentary from a former senior executive in the U.S. Department of Health & Human Services
No comments:
Post a Comment